Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J-L Misset

Showing results (31-40 of 230) with videos related to

Pageof 23
Sort By:
International Journal of Clinical Pharmacology Research|January 1, 1988
CNS prophylaxis using a triple intrathecal drug therapy without cranial irradiation in acute lymphoblastic leukaemiaI Asfour, J L Misset, G Mathe, et al.
Bulletin Du Cancer|January 1, 1986
[Advanced cancer of the prostate. Treatment with an LH-RH agonist, D-Trp-6-LH-RH]G Mathé, J L Misset, M L Vovan, et al.
Journal of the National Cancer Institute|July 20, 1994
Feasibility of high-dose platinum delivery with combined carboplatin and oxaliplatinJ F Llory, P Soulie, E Cvitkovic, et al.
Anti-Cancer Drugs|April 22, 1999
Cellular pharmacology of the combination of oxaliplatin with topotecan in the IGROV-1 human ovarian cancer cell lineF Goldwasser, L Bozec, N Zeghari-Squalli, et al.
Journal of Chemotherapy (Florence, Italy)|June 1, 1989
The prognostic implications of an immunological classification of acute lymphoblastic leukemiaI Asfour, G Mathe, J L Misset, et al.
Bulletin De La Societe Des Sciences Medicales Du Grand-Duche De Luxembourg|March 1, 1989
Identification of mammary metastatic cells in the bone marrow as a marker of a minimal residual disease and of their proliferative index as a factor of prognosis--an immunocytologic study with monoclonal antibodiesM Ginsbourg, M Musset, J L Misset, et al.
Annals of the New York Academy of Sciences|January 1, 1991
When should the immune clock be reset? From circadian pharmacodynamics to temporally optimized drug deliveryF Lévi, C Canon, M Dipalma, et al.
Lancet (London, England)|May 17, 1986
Timing of maintenance chemotherapy for childhood acute lymphoblastic leukaemiaF Lévi, F Bailleul, J L Misset, et al.
Critical Reviews in Oncology/Hematology|August 11, 2000
Oxaliplatin clinical activity: a reviewJ L Misset, H Bleiberg, W Sutherland, et al.
La Semaine Des Hopitaux : Organe Fonde Par L'Association D'Enseignement Medical Des Hopitaux De Paris|March 26, 1972
[Tuberculosis of the cranial vault]G Manigand, A Cohen de Lara, J L Misset, et al.
Pageof 23

Showing results (31-40 of 230) with videos related to

Sort By:
Pageof 23
International Journal of Clinical Pharmacology Research|January 1, 1988
CNS prophylaxis using a triple intrathecal drug therapy without cranial irradiation in acute lymphoblastic leukaemiaI Asfour, J L Misset, G Mathe, et al.
Bulletin Du Cancer|January 1, 1986
[Advanced cancer of the prostate. Treatment with an LH-RH agonist, D-Trp-6-LH-RH]G Mathé, J L Misset, M L Vovan, et al.
Journal of the National Cancer Institute|July 20, 1994
Feasibility of high-dose platinum delivery with combined carboplatin and oxaliplatinJ F Llory, P Soulie, E Cvitkovic, et al.
Anti-Cancer Drugs|April 22, 1999
Cellular pharmacology of the combination of oxaliplatin with topotecan in the IGROV-1 human ovarian cancer cell lineF Goldwasser, L Bozec, N Zeghari-Squalli, et al.
Journal of Chemotherapy (Florence, Italy)|June 1, 1989
The prognostic implications of an immunological classification of acute lymphoblastic leukemiaI Asfour, G Mathe, J L Misset, et al.
Bulletin De La Societe Des Sciences Medicales Du Grand-Duche De Luxembourg|March 1, 1989
Identification of mammary metastatic cells in the bone marrow as a marker of a minimal residual disease and of their proliferative index as a factor of prognosis--an immunocytologic study with monoclonal antibodiesM Ginsbourg, M Musset, J L Misset, et al.
Annals of the New York Academy of Sciences|January 1, 1991
When should the immune clock be reset? From circadian pharmacodynamics to temporally optimized drug deliveryF Lévi, C Canon, M Dipalma, et al.
Lancet (London, England)|May 17, 1986
Timing of maintenance chemotherapy for childhood acute lymphoblastic leukaemiaF Lévi, F Bailleul, J L Misset, et al.
Critical Reviews in Oncology/Hematology|August 11, 2000
Oxaliplatin clinical activity: a reviewJ L Misset, H Bleiberg, W Sutherland, et al.
La Semaine Des Hopitaux : Organe Fonde Par L'Association D'Enseignement Medical Des Hopitaux De Paris|March 26, 1972
[Tuberculosis of the cranial vault]G Manigand, A Cohen de Lara, J L Misset, et al.
Pageof 23